Pontifax


Pontifax is a healthcare-dedicated venture capital firm founded in 2004 with approximately $1.2 billion under management. The firm focuses exclusively on life sciences and invests across all development stages, seeking transformative healthcare technologies. Pontifax pursues company creation as well as investments in existing management teams and applies a hands-on approach to portfolio management, providing strategic guidance, network access and capital markets / M&A support.

Industries

biotechnology
medical-device
pharmaceutical
venture-capital-b37d

Nr. of Employees

small (1-50)

Pontifax


Portfolio

Clinical-stage company developing immunotherapies targeting KLRG1-expressing cells.

#BioPharma

Developing differentiated antibody-drug conjugates (ADCs) for underserved cancers.

#BioPharma

Develops novel antibody-drug conjugates (ADCs) for cancer.

#BioPharma

Develops next-generation cell immunotherapies; acquired Applied Immune Technologies in 2016.

#BioPharma

Developing antibody therapies that induce tissue regeneration.

#BioPharma

Developing oral enzyme therapeutics for rare kidney metabolic disorders.

#BioPharma

View All Portfolio Items

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.